Lilly and Boehringer Ingelheim have gained EU approval for their biosimilar version of Sanofi's blockbuster insulin product Lantus (insulin glargine). The Europe-wide approval is the first ever ...
Sales of Lantus were around €6 billion (around $6.5 billion) at their peak but started to decline in 2014 after the first biosimilars were approved in Europe, and as downward pressure on insulin ...
Hosted on MSN27d
Newsom committed California to making its own insulin. It’s at least a year behind his scheduleThe FDA approved Semglee in 2021, the first interchangeable biosimilar insulin ... meaning it can be substituted at the pharmacy for Lantus, the brand name insulin glargine, without needing ...
An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...
Express Scripts even blocked both the branded reference product – Lantus - and the lower-priced biosimilar. There may be another impediment to Amjevita’s uptake, regardless of which version is ...
Oncology, ophthalmology, and pegfilgrastim biosimilars reached 81% market share within five years, while others lagged at 26%. CMS increased biosimilar reimbursement to ASP plus 8% of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback